This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ViroMed-bluebird CAR-T Program
Drug Names(s): ViroMed bluebird CAR T Program
Description: ViroMed bluebird CAR T Program utilizes bluebird's chimeric anttigen receptor T cell therapies and ViroMed's humanized antibody to an undisclosed cancer target.
blubird and ViroMed
In December 2015, bluebird bio and ViroMed announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMeds proprietary humanized antibody to an undisclosed cancer target for solid tumors. Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target. Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved. ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as...See full deal structure in Biomedtracker
Partners: ViroMed Co., Ltd.
ViroMed-bluebird CAR-T Program News
Additional information available to subscribers only: